AstraZeneca’s Tagrisso plus chemotherapy improves overall survival in EGFR-mutated advanced lung cancer
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
Recommendation based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years
Approval based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months vs. standard of care
Recommendation based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
First and only TROP2-directed therapy approved in the US for the treatment of lung cancer
Back-to-back plenary presentations for LAURA and ADRIATIC Phase III trials reinforce the potential of Tagrisso and Imfinzi in early lung cancer settings
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
Combination shows consistent benefit across prespecified post-progression outcomes
The company has received five final approvals
Subscribe To Our Newsletter & Stay Updated